The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated ...

The drug daraxonrasib could be a potential new treatment to double the survival of advanced pancreatic cancer patients, a groundbreaking new clinical trial suggests. Pancreatic cancer patients often ...

An experimental pancreatic cancer drug is predicted to revolutionize the way the cancer is treated, according to oncologists.

The FDA has opened an expanded access program for daraxonrasib, an investigational drug showing encouraging results in pancreatic ductal adenocarcinoma with RAS mutations. Phase I/II trials reported ...

Good day, and thank you for standing by. Welcome to the Revolution Medicines Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...

For decades, pancreatic cancer patients have faced some of the bleakest odds in medicine. Treatments barely moved the needle.

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...

The investigational drug daraxonrasib, now available through an early access program, demonstrated promising efficacy in ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; ...

An experimental drug from Revolution Medicines that nearly ​doubled survival time for patients with advanced pancreas cancer ...